ON DEMAND WEBINAR:

How a Novel Sepsis Diagnostic Enables Life-Saving Decisions: New Real-World Evidence

Early detection of sepsis in the emergency department remains a major clinical challenge, as traditional biomarkers often rely on indirect measures of disease and can involve lengthy turnaround times. Clinicians are frequently forced to make high-stakes treatment decisions before sepsis is clearly identified or ruled out. This webinar explores a new, evidence-based approach to early sepsis detection—cellular host response diagnostics—which directly assess immune dysregulation to help identify sepsis risk earlier and more accurately.

Experts from the Froedtert and Medical College of Wisconsin Health Network will share real-world study results evaluating IntelliSep®, an FDA-cleared host response diagnostic test that aids in the detection of sepsis with organ dysfunction manifesting within 3 days after testing in adults presenting to the ED. At their hospital, researchers observed significant differences in mortality and length of stay among patients with suspected infection who received IntelliSep compared to those who did not.

Register now to learn how this novel diagnostic was implemented in ED and laboratory workflows and how evidence-based strategies like host response diagnostics can improve early sepsis risk stratification and clinical decision-making at your hospital.

Key Learning Objectives:

  1. Understand why early sepsis detection in the ED remains difficult and evaluate the limitations of traditional diagnostic approaches.
  2. Learn about the value of using cellular host response diagnostics for early, first-line risk stratification of sepsis likelihood in the ED before pathogen testing is performed.
  3. Discover how the IntelliSep® sepsis test works, and how it can easily be integrated into ED and laboratory workflows to support clinical decision-making.
  4. Review real-world results from Froedtert Hospital, where they observed 42% lower mortality rate and nearly two-day shorter hospital length of stay among patients with suspected infection who received IntelliSep compared with those who did not.
thomas-carver-185-l
Thomas Carver, MD, FACS
Professor of Surgery and Senior Medical Director of Critical Care Services at the Medical College of Wisconsin
nathan-ledeboer-l
Nathan Ledeboer, PhD
Professor and Chief of Clinical Pathology in the Department of Pathology and Laboratory Medicine at the Medical College of Wisconsin and the Associate Chief Medical Laboratory Officer at Froedtert Health
CONNECT WITH US

Stay in Touch with the Future of Sepsis Care